文献速递临床试验与 GCP

新型手辅助腹腔镜对比传统腹腔镜右半结肠切除术治疗右半结肠癌:随机对照试验研究方案

A novel hand-assisted laparoscopic versus conventional laparoscopic right hemicolectomy for right colon cancer: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-07-26

本研究为单中心、开放标签、非劣效性随机对照试验,将右半结肠癌患者按1:1:1随机分入手辅助腹腔镜联合完整结肠系膜切除、D3淋巴结清扫及完全「无接触」隔离技术组、腹腔镜联合完整结肠系膜切除、D3淋巴结清扫及完全「无接触」隔离技术组或传统腹腔镜联合完整结肠系膜切除及D3淋巴结清扫组,主要终点包括安全性、有效性、肿瘤学清除及3年无病生存、无进展生存和总生存。

要点

  • 手辅助腹腔镜联合完整结肠系膜切除、D3淋巴结清扫及完全「无接触」隔离技术用于右半结肠切除术,据既往临床实践可行且安全并具技术优点。
  • 该技术的可行性、短期微创优势、长期肿瘤学优越性及潜在完全「无接触」隔离技术获益需前瞻性随机对照试验确认。
  • 试验假设手辅助腹腔镜联合完整结肠系膜切除方案对右半结肠癌D3根治性切除可行,且较传统腹腔镜手术提供短期安全性和长期肿瘤学优越性。

核心结论

  • 本试验将为右半结肠切除术中手辅助腹腔镜联合完整结肠系膜切除、D3淋巴结清扫及完全「无接触」隔离技术的可行性、安全性及潜在完全「无接触」隔离技术获益提供有价值的临床证据。
  • 研究假设手辅助腹腔镜联合完整结肠系膜切除方案对右半结肠癌D3根治性切除可行,且较传统腹腔镜手术提供短期安全性和长期肿瘤学优越性。

研究设计与样本

  • 单中心、开放标签、非劣效性随机对照试验。
  • 符合条件参与者按1:1:1比例通过集中随机化列表随机分入手辅助腹腔镜联合完整结肠系膜切除、D3淋巴结清扫及完全「无接触」隔离技术组,或腹腔镜联合完整结肠系膜切除、D3淋巴结清扫及完全「无接触」隔离技术组,或传统腹腔镜联合完整结肠系膜切除及D3淋巴结清扫组。

主要发现

  • 据既往临床实践,手辅助腹腔镜联合完整结肠系膜切除、D3淋巴结清扫及完全「无接触」隔离技术用于右半结肠切除术不仅可行且安全,并具若干技术优点。

关键数值与推荐

  • 主要终点包括安全性、有效性、肿瘤学清除及3年无病生存、无进展生存和总生存。
  • 次要终点包括手术结局(手术时间、失血量、切口长度)。
  • 次要终点包括病理评估(手术平面分级、近端和远端切缘长度、肿瘤与中央动脉高位结扎点距离、最近肠壁与同高位结扎点距离、切除肠系膜面积、淋巴脂肪组织链宽度、中央淋巴脂肪链长度、收获淋巴结数)。
  • 次要终点包括术后结局(疼痛强度、术后炎症和免疫反应、术后恢复)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although conventional laparoscopic and hand-assisted laparoscopic surgery for colorectal cancer is widely used today, there remain many technical challenges especially for right colon cancer in obese patients. Herein, we develop a novel hand-assisted laparoscopic surgery (HALS) with complete mesocolic excision (CME), D3 lymphadenectomy, and a total "no-touch" isolation technique (HALS-CME) in right hemicolectomy to overcome these issues. According to previous clinic practice, this novel procedure is not only feasible and safe but has several technical merits. However, the feasibility, short-term minimally invasive virtues, long-term oncological superiority, and potential total "no-touch" isolation technique benefits of HALS-CME should be confirmed by a prospective randomized controlled trial. METHODS/DESIGN: This is a single-center, open-label, noninferiority, randomized controlled trial. Eligible participants will be randomly assigned to the HALS-CME group or to the laparoscopic surgery with CME, D3 lymphadenectomy, and total "no-touch" isolation technique (LAP-CME) group, or to conventional laparoscopic surgery with CME and D3 lymphadenectomy (cLAP) group at a 1:1:1 ratio using a centralized randomization list. Primary endpoints include safety, efficacy, and being oncologically clear, and 3-year disease-free, progression-free, and overall survival. Second endpoints include operative outcomes (operation time, blood loss, and incision length), pathologic evaluation (grading the plane of surgery, length of proximal and distal resection margins, distance between the tumor and the central arterial high tie, distance between the nearest bowel wall and the same high tie, area of mesentery resected, width of the chain of lymph-adipose tissue, length of the central lymph-adipose chain, number of harvested lymph nodes), and postoperative outcomes (pain intensity, postoperative inflammatory and immune responses, postoperative recovery). DISCUSSION: This trial will provide valuable clinical evidence for the feasibility, safety, and potential total "no-touch" isolation technique benefits of HALS-CME for right hemicolectomy. The hypothesis is that HALS-CME is feasible for the radical D3 resection of right colon cancer and offers short-term safety and long-term oncological superiority compared with conventional laparoscopic surgery. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02625272 . Registered on 8 December 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yang X, Wu Q, Jin C, et al. A novel hand-assisted laparoscopic versus conventional laparoscopic right hemicolectomy for right colon cancer: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28747220. doi:10.1186/s13063-017-2084-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。